Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.